Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8), is pleased to announce that it’s US subsidiary, Advanced Proteome Therapeutics Inc. (“APTI”), has initiated a project to identify and generate therapeutic candidates against SARS-CoV-2, the virus which causes COVID-19.
Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8), is pleased to announce that it’s US subsidiary, Advanced Proteome Therapeutics Inc. (“APTI”), has initiated a collaboration with Dr. Brian Zeglis at the City University of New York to test APTI’s site specific conjugation technology in the rapidly growing field of radioimmunoconjugates (RICs). APTI will prepare RICs using its proprietary conjugation technology with antibodies targeting the HER2 receptor. The HER2 receptor is expressed on many malignancies with approved targeted therapeutics for breast and gastric cancer. Under the collaboration, RICs produced with APTI conjugation technology will be chemically characterized, imaged by PET and in vivo bio-distribution evaluated.
